Skip to main content
. 2014 Oct 25;6(5):3394–3408. doi: 10.18632/oncotarget.2583

Figure 3. Synergistic effects of Chk1 and Wee1 inhibitors in MCL cell lines.

Figure 3

(A) Normalized IC50 isobologram showing the synergistic effects of the combination in 10 MCL cell lines (see legend). (B) JeKo-1 cell survival after 72 hrs of treatment with PF-00477736 10 nM, MK-1775 50 nM or both drugs. Data are percentages of untreated cells and represent the mean ±SD of three independent experiments. (C) (upper panel) Western blot analysis showing pS317-Chk1, Chk1, pY15-CDK1, CDK1 and actin protein levels in JeKo-1 cells, 24 hrs after treatment with the single drugs or the combination. (lower panel) Western blot analysis showing pY15-CDK2, CDK2, pY15/T14-CDK1, CDK1 and actin protein levels in JeKo-1 cells, 48 hrs after treatment with the single drugs or the combination.